No Picture
News

Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

SAN DIEGO, July 17, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial … […]

No Picture
News

TMRW Robotic Process Automation Platform Goes Live at San Diego Fertility Center, Vios Fertility Institute – Chicago and Reproductive Medicine Associates of New York

Multi-Site Study to Track Improvements to Safety and Results Achieved through Process Automation for the Preservation of Embryos and Other Fertility Cells

NEW YORK and CHICAGO and SAN DIEGO, July 16, 2019 /PRNewswire/ — TMRW, the creator of the firs… […]

No Picture
News

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson’s Disease

– FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa- Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 26, 2020- New D… […]

No Picture
News

Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155

SAN DIEGO, July 9, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati’s investiga… […]

No Picture
News

Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.The smaller delivery volume enables use of established drug container and device technology developed f… […]

No Picture
News

MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors

SAN DIEGO, July 3, 2019 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Tamar Howson, M.S., MBA, to its board of directo… […]